Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San

  Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the
      31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire

SAN FRANCISCO, Jan. 4, 2013

SAN FRANCISCO, Jan. 4, 2013 /PRNewswire/ --Nektar Therapeutics' (Nasdaq:
NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to
present at the upcoming 31st Annual J.P. Morgan Healthcare Conference in San
Francisco at the Westin St. Francis Hotel on Wednesday, January 9, 2013 at
8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the
Investor Relations, Events Calendar section of the Nektar website:
http://www.nektar.com. This Webcast will be available for replay until
February 10, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet
for the treatment of opioid-induced constipation. This agreement also
includes NKTR-119, an earlier stage development program that is a
co-formulation of naloxegol and an opioid. In its proprietary pain pipeline,
Nektar is developing NKTR-181, a novel mu-opioid analgesic candidate for
chronic pain conditions, which is in Phase 2 development in osteoarthritis
patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in
development to treat acute pain is in Phase 1 clinical development. In
oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3
clinical study (the BEACON study) for the treatment of metastatic breast
cancer and is also in Phase 2 studies for the treatment of ovarian and
colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including
Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta®
for neutropenia. Additional development-stage products that leverage Nektar's
proprietary technology platform include Baxter's BAX 855, a long-acting
PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at http://www.nektar.com.

Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585

SOURCE Nektar Therapeutics

Website: http://www.nektar.com
 
Press spacebar to pause and continue. Press esc to stop.